EE200400056A - 2-alkoksüfenüül-asendatud imidasotriasinoonide kasutamine - Google Patents
2-alkoksüfenüül-asendatud imidasotriasinoonide kasutamineInfo
- Publication number
- EE200400056A EE200400056A EEP200400056A EEP200400056A EE200400056A EE 200400056 A EE200400056 A EE 200400056A EE P200400056 A EEP200400056 A EE P200400056A EE P200400056 A EEP200400056 A EE P200400056A EE 200400056 A EE200400056 A EE 200400056A
- Authority
- EE
- Estonia
- Prior art keywords
- upto
- alkoxycarbonyl
- cooh
- alkyl
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10135815A DE10135815A1 (de) | 2001-07-23 | 2001-07-23 | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
PCT/EP2002/007959 WO2003011262A2 (de) | 2001-07-23 | 2002-07-17 | Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von erkrankungen, die im zusammenhang mit cgmp-regulierten vorgängen stehen |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200400056A true EE200400056A (et) | 2004-04-15 |
Family
ID=7692784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200400056A EE200400056A (et) | 2001-07-23 | 2002-07-17 | 2-alkoksüfenüül-asendatud imidasotriasinoonide kasutamine |
Country Status (28)
Country | Link |
---|---|
US (3) | US6930108B2 (ja) |
EP (2) | EP1733728A3 (ja) |
JP (1) | JP2005504751A (ja) |
KR (1) | KR20040032865A (ja) |
CN (1) | CN1649593A (ja) |
AT (1) | ATE442144T1 (ja) |
AU (1) | AU2002319296B2 (ja) |
BG (1) | BG108533A (ja) |
BR (1) | BR0211359A (ja) |
CA (1) | CA2454414A1 (ja) |
CO (1) | CO5560536A2 (ja) |
CZ (1) | CZ2004128A3 (ja) |
DE (2) | DE10135815A1 (ja) |
EC (1) | ECSP044956A (ja) |
EE (1) | EE200400056A (ja) |
ES (1) | ES2330418T3 (ja) |
HR (1) | HRP20040065A2 (ja) |
HU (1) | HUP0500734A3 (ja) |
IL (1) | IL159840A0 (ja) |
MA (1) | MA26128A1 (ja) |
MX (1) | MXPA04000675A (ja) |
NO (1) | NO20040294L (ja) |
NZ (1) | NZ530703A (ja) |
PL (1) | PL373392A1 (ja) |
RU (1) | RU2321406C9 (ja) |
SK (1) | SK442004A3 (ja) |
UA (1) | UA76997C2 (ja) |
WO (1) | WO2003011262A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するイミダゾトリアジノン誘導体 |
DE102004023069A1 (de) | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
DE102004038328A1 (de) * | 2004-08-06 | 2006-03-16 | Bayer Healthcare Ag | Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
ES2433661T3 (es) | 2005-04-19 | 2013-12-12 | Takeda Gmbh | Roflumilast para el tratamiento de hipertensión pulmonar |
WO2011079778A1 (en) * | 2009-12-30 | 2011-07-07 | China Shanghai Fochon Pharmaceutical Co Ltd | 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors |
AT512084A1 (de) * | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
SG10201911076QA (en) * | 2016-12-16 | 2020-01-30 | Cystic Fibrosis Found | Bycyclic heteroaryl derivatives as cftr potentiators |
CN113461694A (zh) * | 2021-08-05 | 2021-10-01 | 广东西捷药业有限公司 | 一种伐地那非类似物及其合成方法和应用 |
CN113583003A (zh) * | 2021-08-05 | 2021-11-02 | 广东西捷药业有限公司 | 一种伐地那非类似物及其合成方法和应用 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE791025A (fr) | 1971-11-19 | 1973-05-07 | Allen & Hanburys Ltd | Composes heterocycliques |
GB1457873A (en) | 1973-01-04 | 1976-12-08 | Allen & Hanburys Ltd | Imidazotriazines |
DK109578A (da) | 1977-03-25 | 1978-09-26 | Allen & Hanburys Ltd | Fremgangsmaade til fremstilling af heterocycliske forbindelser |
US4308384A (en) | 1978-09-18 | 1981-12-29 | Glaxo Group Limited | Production of triazinones |
US4479210A (en) * | 1982-11-19 | 1984-10-23 | U.S. Philips Corporation | Record-disc player |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US5656629A (en) * | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
DE69622031T2 (de) * | 1995-04-10 | 2002-12-12 | Fujisawa Pharmaceutical Co., Ltd. | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN |
CN1211238A (zh) * | 1995-12-28 | 1999-03-17 | 藤泽药品工业株式会社 | 苯并咪唑衍生物 |
CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
EP2295436A1 (de) * | 1997-11-12 | 2011-03-16 | Bayer Schering Pharma AG | 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren |
DE19812462A1 (de) * | 1998-03-23 | 1999-09-30 | Bayer Ag | 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid |
CA2314339C (en) * | 1997-12-12 | 2009-09-08 | Cell Pathways, Inc. | N-benzyl-3-indenylacetamide derivatives for treating neoplasia |
US6087368A (en) * | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
DE19827640A1 (de) | 1998-06-20 | 1999-12-23 | Bayer Ag | 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone |
IL132406A0 (en) * | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
US6225315B1 (en) * | 1998-11-30 | 2001-05-01 | Pfizer Inc | Method of treating nitrate-induced tolerance |
FR2792634B1 (fr) * | 1999-04-20 | 2001-06-01 | Synthelabo | Derives de 2-alcoxy-cyclobutene-3,4-dione leur preparation et leur application en therapeutique |
IL130968A (en) * | 1999-07-15 | 2002-12-01 | Shmuel Simon | Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss |
WO2001032170A1 (en) * | 1999-09-13 | 2001-05-10 | Swope David M | Composition and method for decreasing neurologic symptomatology |
DE19943815A1 (de) * | 1999-09-14 | 2001-03-15 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
US6503908B1 (en) * | 1999-10-11 | 2003-01-07 | Pfizer Inc | Pharmaceutically active compounds |
DE50013571D1 (de) * | 1999-10-12 | 2006-11-16 | Lilly Icos Llc | Arzneimittel zur behandlung von neuropathien |
IL152925A (en) * | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
GB0008694D0 (en) * | 2000-04-07 | 2000-05-31 | Novartis Ag | Organic compounds |
CA2407031A1 (en) * | 2000-04-19 | 2001-10-25 | Lilly Icos Llc | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
CN1630532A (zh) * | 2000-04-19 | 2005-06-22 | 约翰斯霍普金斯大学 | 预防和治疗胃肠疾病的方法 |
JP2004506009A (ja) * | 2000-08-11 | 2004-02-26 | ファイザー・インク | インスリン抵抗性症候群の治療 |
MXPA03001717A (es) * | 2000-08-30 | 2003-09-22 | Lilly Icos Llc | METODO PARA EL TRATAMIENTO DE LA MIGRAnA. |
GB0025782D0 (en) * | 2000-10-20 | 2000-12-06 | Pfizer Ltd | Use of inhibitors |
MXPA03006936A (es) * | 2001-02-02 | 2003-11-18 | Pfizer | Tratamiento de diabetes mellitus. |
DE10107639A1 (de) * | 2001-02-15 | 2002-08-22 | Bayer Ag | 2-Alkoxyphenyl-substituierte Imidazotriazinone |
CA2449163C (en) * | 2001-05-09 | 2010-07-13 | Bayer Healthcare Ag | New use of 2-phenyl-substituted imidazotriazinones |
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
JP2005527510A (ja) * | 2002-03-06 | 2005-09-15 | セレジー ファーマシューティカルズ インコーポレーティッド | 癌の治療において一酸化窒素模倣体を使用するための製剤および方法 |
-
2001
- 2001-07-23 DE DE10135815A patent/DE10135815A1/de not_active Withdrawn
-
2002
- 2002-07-17 US US10/483,462 patent/US6930108B2/en not_active Expired - Fee Related
- 2002-07-17 DE DE50213840T patent/DE50213840D1/de not_active Expired - Fee Related
- 2002-07-17 AU AU2002319296A patent/AU2002319296B2/en not_active Ceased
- 2002-07-17 CN CNA028144759A patent/CN1649593A/zh active Pending
- 2002-07-17 CZ CZ2004128A patent/CZ2004128A3/cs unknown
- 2002-07-17 IL IL15984002A patent/IL159840A0/xx unknown
- 2002-07-17 EE EEP200400056A patent/EE200400056A/xx unknown
- 2002-07-17 EP EP06017257A patent/EP1733728A3/de not_active Withdrawn
- 2002-07-17 MX MXPA04000675A patent/MXPA04000675A/es active IP Right Grant
- 2002-07-17 CA CA002454414A patent/CA2454414A1/en not_active Abandoned
- 2002-07-17 ES ES02748858T patent/ES2330418T3/es not_active Expired - Lifetime
- 2002-07-17 HU HU0500734A patent/HUP0500734A3/hu unknown
- 2002-07-17 NZ NZ530703A patent/NZ530703A/en unknown
- 2002-07-17 UA UA2004021279A patent/UA76997C2/uk unknown
- 2002-07-17 EP EP02748858A patent/EP1474150B1/de not_active Expired - Lifetime
- 2002-07-17 WO PCT/EP2002/007959 patent/WO2003011262A2/de active Application Filing
- 2002-07-17 JP JP2003516493A patent/JP2005504751A/ja active Pending
- 2002-07-17 PL PL02373392A patent/PL373392A1/xx not_active Application Discontinuation
- 2002-07-17 AT AT02748858T patent/ATE442144T1/de not_active IP Right Cessation
- 2002-07-17 SK SK44-2004A patent/SK442004A3/sk not_active Application Discontinuation
- 2002-07-17 BR BR0211359-7A patent/BR0211359A/pt not_active IP Right Cessation
- 2002-07-17 RU RU2004105265/15A patent/RU2321406C9/ru not_active IP Right Cessation
- 2002-07-17 KR KR10-2004-7001050A patent/KR20040032865A/ko not_active Application Discontinuation
-
2004
- 2004-01-14 BG BG108533A patent/BG108533A/bg unknown
- 2004-01-19 EC EC2004004956A patent/ECSP044956A/es unknown
- 2004-01-22 NO NO20040294A patent/NO20040294L/no not_active Application Discontinuation
- 2004-01-22 MA MA27497A patent/MA26128A1/fr unknown
- 2004-01-22 HR HRP20040065 patent/HRP20040065A2/xx not_active Application Discontinuation
- 2004-02-23 CO CO04015666A patent/CO5560536A2/es not_active Application Discontinuation
-
2005
- 2005-06-17 US US11/156,082 patent/US7276504B2/en not_active Expired - Fee Related
-
2007
- 2007-10-01 US US11/906,382 patent/US20080085897A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200400056A (et) | 2-alkoksüfenüül-asendatud imidasotriasinoonide kasutamine | |
RU2429226C2 (ru) | Ингибиторы пролилгидроксилазы и способы их применения | |
US9409902B2 (en) | Modulators of HEC1 activity and methods therefor | |
ES2387388T3 (es) | Compuesto de adenina y uso del mismo | |
CN102203063B (zh) | 咔唑化合物及其治疗用途 | |
US10501433B2 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
JP5295230B2 (ja) | 粘液分泌の刺激剤としての3’,4’,5−トリメトキシフラボン誘導体、その方法、および上記化合物を含んでなる医薬組成物 | |
US20130281397A1 (en) | Treatment of diseases by epigenetic regulation | |
CN116850163A (zh) | 用于治疗糖尿病性视网膜病及其他眼科疾病的方法 | |
US11219625B2 (en) | Inhibitors of N-linked glycosylation and methods using same | |
TW200406202A (en) | Inhibitors of cyclin-dependent kinases and their use | |
PT2287155E (pt) | Composto de aciltioureia ou um seu sal, e sua utilização | |
US5990117A (en) | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives | |
CN110240557A (zh) | 吡咯烷酰胺衍生物及其用途 | |
NO20034560D0 (no) | Middel for topisk oftalmisk behandling av okul¶re inflammasjonssykdommer | |
Cuevas et al. | Therapeutic response of rosacea to dobesilate | |
KR20140056164A (ko) | 신규 푸라논 유도체 | |
Du et al. | Novel substituted 4-(Arylethynyl)-Pyrrolo [2, 3-d] pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice | |
CN111072604B (zh) | α-氨基酰胺衍生物及其用途 | |
CN108912029B (zh) | 含氮杂环酰胺衍生物及其用途 | |
US20060252780A1 (en) | Fused pyrimidine derivatives | |
CN115397423A (zh) | 用于治疗mps1的组合疗法 | |
KR20230081602A (ko) | Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물 | |
JP2024028808A (ja) | 皮膚障害の治療 | |
JP2020189788A (ja) | 睡眠誘導剤である複素環化合物 |